Research in my laboratory is focused on the discovery and characterization of cancer biomarkers and novel druggable targets. In my lab we use integrative genomic approaches to identify genetic and cellular properties of tumors that explain systems-level variation in cancer aggressiveness and treatment response. We employ next-generation sequencing technologies such as whole-exome sequencing, bulk RNA-Seq and single-cell RNA-Seq to study how the molecular and cellular composition of tumors impacts tumor form and phenotype. In breast cancers and other solid tumors, we investigate the dynamics of tumor-immune interactions on a population scale. Our work shows that biomarkers predictive of immune-mediated patient outcomes reflect differences in tumor immunological configurations, as well as states of molecular polarization that favor immunosuppressive or immunostimulatory phenotypes. Using multivariable statistics to guide the discovery process, we have identified novel molecular interactions between tumors and their immunological environments that are the focus of ongoing mechanistic studies involving immunocompetent mouse tumor models and immune functional characterization assays.